tirzepatide for binge eating disorder GLP-1 Agonist Disorder: Evidence and Safety Tirzepatide for Binge Eating Disorder:

However, this specific use has not been validated in clinical trials

Self-administration can be dangerous

Evidence-based 2:1 glucose-to-fructose ratio, 250mg sodium per serving, and clean carbs that absorb without the GI drama

In addition to these widely used AOMs, Exenatide, one of the earliest GLP-1 RAs approved by the FDA and EMA for T2DM management, is not indicated for weight management but remains clinically relevant, particularly in older adults with comorbid obesity and T2DM, given its long-term clinical experience and established tolerability profile [26,27,28]

Now, with its ability to be administered orally, semaglutide offers great opportunities in the treatment of T2D as well as other potential disease groups